RARA CRAFT DATABASE for FDA Medical Devices
510(k)K153050

FDA DEVICE FACTS

Rapid Single/Multi-drug Test Cup, Rapid Single/Multi-drug Test Dipcard

Co-Innovation Biotech Co., Ltd.

FDA-sourced product information for medical-device development research. Use the official FDA sources at the end of this page when the original public document wording is needed.医療機器開発の調査用に、FDA の公開情報から取った製品情報を示しています。公開文書の原文が必要なときは、このページの最後にある FDA の公式な出典をご覧ください。

DECISION DATEApril 26, 2016PRODUCT CODEDJG

Indications for use

Rapid Single/Multi-drug Test Cup and Rapid Single/Multi-drug Test Dipcard is a rapid drug screening test designed to qualitatively detect the presence of drugs and drug metabolites in human urine at the following cut-off concentrations: Test Calibrator Cut-off level Marijuana (THC) Delta-9-THC-COOH 50 ng/mL Cocaine (COC) Benzoylecgonine 300 ng/mL Amphetamine (AMP) D-Amphetamine 1000 ng/mL Methamphetamine (MET) D-Methamphetamine 1000 ng/mL Morphine 2000 (MOP) Morphine 2000 ng/mL Barbiturates (BAR) Secobarbital 300 ng/mL Benzodiazepines (BZO) Oxazepam 300 ng/mL Methylenedioxymethamphetamine (MDMA) 3,4-Methylenedioxymethamphetamine 500 ng/mL Methadone (MTD) Methadone 300 ng/mL Oxycodone (OXY) Oxycodone 100 ng/mL Phencyclidine (PCP) Phencyclidine 25 ng/mL Buprenorphine(BUP) Buprenorphine 10ng/mL 2-ethylidene-1, 5-dimethyl-3, 2-ethylidene-1, 5-dimethyl-3, 300 ng/mL 3-diphenylpyrrolidine(EDDP) 3-diphenylpyrrolidine Morphine(MOP300) Morphine 300 ng/mL Propoxyphene(PPX) Propoxyphene 300 ng/mL Tri-cyclic Antidepressants (TCA) Nortriptyline 1000 ng/mL The tests contain two formats:1) Test Cup and 2) Test Dipcard. The tests may be configured as single drug tests or multiple drug tests in any combination of the drug analytes listed in the table above up to a maximum of 15 analytes. Only one cutoff concentration will be included per analyte per device. The tests are intended for in vitro diagnostics use. They are intended for prescription use including point of care sites and over-the-counter use. The tests will yield preliminary positive results when prescription drugs Barbiturates, Buprenorphine, Benzodiazepine, Methadone, Propoxyphene or Tricyclic Antidepressants are ingested, even at or above therapeutic doses. There are no uniformly recognized drug levels for Barbiturates, Buprenorphine, Benzodiazepine, Propoxyphene and Tricyclic Antidepressants in urine. This assay provides only a preliminary analytical test result. Gas Chromatography/Mass spectrometry (GC/MS) is the preferred confirmatory method. Clinical consideration and professional judgment should be applied to any drug of abuse test result, particularly when preliminary positive results are indicated.

See the full product information製品情報をすべて見るには

Device description, AI/software, PCCP, evaluation and limitations are available with an account: seven days of full access after free registration, then with the paid plan.機器の説明、AI・ソフトウェア、PCCP、評価、制限事項は、アカウントでご覧いただけます。無料登録から 7 日間はすべて利用でき、その後は有料プランでご利用いただけます。

Start free 7-day access7日間無料で利用するLog inログイン

OFFICIAL FDA SOURCES

FDA Record and Public Document Status

Record and document link states are stored separately.FDA Record と公開文書のリンクの状態は、別々に記録しています。

Information reviewed:情報の確認日: September 3, 2026